Viking Therapeutics (VKTX) Competitors $31.88 -2.15 (-6.32%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$32.30 +0.42 (+1.32%) As of 04:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VKTX vs. MDGL, LLY, GMAB, MRNA, RDY, QGEN, VTRS, ASND, VRNA, and BBIOShould you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), and BridgeBio Pharma (BBIO). These companies are all part of the "medical" sector. Viking Therapeutics vs. Its Competitors Madrigal Pharmaceuticals Eli Lilly and Company Genmab A/S Moderna Dr. Reddy's Laboratories Qiagen Viatris Ascendis Pharma A/S Verona Pharma PLC American Depositary Share BridgeBio Pharma Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings. Do analysts prefer MDGL or VKTX? Madrigal Pharmaceuticals presently has a consensus price target of $421.63, suggesting a potential upside of 24.70%. Viking Therapeutics has a consensus price target of $86.92, suggesting a potential upside of 172.66%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Madrigal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more volatility and risk, MDGL or VKTX? Madrigal Pharmaceuticals has a beta of -1.02, indicating that its share price is 202% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Do institutionals & insiders hold more shares of MDGL or VKTX? 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 4.1% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor MDGL or VKTX? In the previous week, Madrigal Pharmaceuticals had 4 more articles in the media than Viking Therapeutics. MarketBeat recorded 19 mentions for Madrigal Pharmaceuticals and 15 mentions for Viking Therapeutics. Madrigal Pharmaceuticals' average media sentiment score of 0.92 beat Viking Therapeutics' score of 0.84 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 12 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Viking Therapeutics 12 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, MDGL or VKTX? Viking Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMadrigal Pharmaceuticals$317.38M23.65-$465.89M-$12.85-26.31Viking TherapeuticsN/AN/A-$109.96M-$1.53-20.84 Is MDGL or VKTX more profitable? Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -54.68%. Viking Therapeutics' return on equity of -19.98% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Madrigal Pharmaceuticals-54.68% -37.72% -27.17% Viking Therapeutics N/A -19.98%-19.38% SummaryViking Therapeutics beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VKTX vs. The Competition Export to ExcelMetricViking TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.83B$3.01B$5.56B$9.47BDividend YieldN/A2.41%4.31%4.17%P/E Ratio-20.8416.5729.3723.99Price / SalesN/A313.98444.7496.71Price / CashN/A42.1735.8458.51Price / Book4.517.818.085.58Net Income-$109.96M-$54.52M$3.26B$265.35M7 Day Performance-2.12%0.41%0.44%-0.07%1 Month Performance15.89%9.93%4.82%1.76%1 Year Performance-37.32%15.18%30.27%25.39% Viking Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VKTXViking Therapeutics3.9602 of 5 stars$31.88-6.3%$86.92+172.7%-40.2%$3.83BN/A-20.8420MDGLMadrigal Pharmaceuticals3.9346 of 5 stars$295.06-1.1%$420.63+42.6%+26.8%$6.57B$317.38M-16.3890Earnings ReportAnalyst ForecastLLYEli Lilly and Company4.9072 of 5 stars$807.23-0.7%$1,012.56+25.4%-5.9%$765.06B$45.04B65.6847,000Trending NewsGMABGenmab A/S3.6734 of 5 stars$23.11-1.3%$37.80+63.6%-18.7%$14.85B$3.12B13.152,682Short Interest ↑Gap DownMRNAModerna4.265 of 5 stars$33.91-0.7%$46.11+36.0%-67.5%$13.12B$3.24B-3.895,800Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionRDYDr. Reddy's Laboratories2.6041 of 5 stars$14.71+0.2%$16.95+15.3%-18.3%$12.29B$3.81B22.3027,811QGENQiagen3.5373 of 5 stars$50.98-1.6%$49.40-3.1%+9.2%$11.34B$1.98B127.885,765Trending NewsEarnings ReportVTRSViatris2.2557 of 5 stars$9.26-1.6%$10.40+12.4%-22.9%$10.87B$14.74B-2.9232,000Dividend AnnouncementShort Interest ↑ASNDAscendis Pharma A/S2.6256 of 5 stars$164.46-1.8%$223.07+35.6%+45.5%$10.08B$368.70M-26.261,017VRNAVerona Pharma PLC American Depositary Share1.7458 of 5 stars$105.09-0.2%$109.00+3.7%+402.8%$8.95B$42.28M-52.5730Trending NewsEarnings ReportInsider TradeBBIOBridgeBio Pharma4.7207 of 5 stars$46.24-0.1%$61.50+33.0%+80.2%$8.77B$221.90M-13.08400Earnings ReportAnalyst ForecastOptions VolumeGap Down Related Companies and Tools Related Companies Madrigal Pharmaceuticals Competitors Eli Lilly and Company Competitors Genmab A/S Competitors Moderna Competitors Dr. Reddy's Laboratories Competitors Qiagen Competitors Viatris Competitors Ascendis Pharma A/S Competitors Verona Pharma PLC American Depositary Share Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VKTX) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VKTX Stock Alerts